James P. Scopa, director at Therapeutic dice (NASDAQ: DICE), made a large insider buy on September 15, according to a new SEC filing.
What happened: On Wednesday, a Form 4 filed by the United States Securities and Exchange Commission showed that Scopa had purchased 6,000 shares of Dice Therapeutics at a price of $ 17.0 per share. The total transaction was for $ 102,000.
As a result of the transaction, Scopa now owns 55,841 shares of the company, valued at $ 2,037,230.
Therapeutic dice the shares are trading up 4.99% to $ 36.48 as of this writing on Friday morning.
Trade commission-free stocks online now with Charles Schwab, a reliable and comprehensive investment firm.
Why Insider Trading Matters
Insider trading should not be used primarily in making an investment decision, but an insider trading can be a big factor in the decision to invest.
In legal terms, an “insider” refers to any shareholder who owns at least 10% of a company. This can include senior executives and large hedge funds. These insiders are required to notify the public of their transactions via a Form 4, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, it indicates that they expect the stock to rise.
Insider selling, on the other hand, can be done for a variety of reasons and doesn’t necessarily mean the seller thinks the stock is going to go down.
Transaction codes to focus on
Investors prefer to focus on transactions that take place in the open market, shown in Table I of Form 4 filing. A P in box 3 indicates a purchase, while S indicates a sale. Transaction code VS indicates the conversion of an option, and the transaction code A indicates that the insider may have been forced to sell shares in order to receive compensation that was promised to him when he was hired by the company.
Check out Dice Therapeutics’ full list of insider trading.